The anti-ovarian cancer effect of RPV modified paclitaxel plus schisandra B liposomes in SK-OV-3 cells and tumor-bearing mice.
The anti-ovarian cancer effect of RPV modified paclitaxel plus schisandra B liposomes in SK-OV-3 cells and tumor-bearing mice.
复制标题
DOI：
10.1016/j.lfs.2021.120013
复制
发表时间：
2021-10
期刊：
影响因子：
6.1
通讯作者：
Lu Zhang;Liang Kong;Si-yu He;Xin-ze Liu;Yang Liu;J. Zang;Rui‐jun Ju;Xue‐tao Li
中科院分区：
文献类型：
--
作者：
Lu Zhang;Liang Kong;Si-yu He;Xin-ze Liu;Yang Liu;J. Zang;Rui‐jun Ju;Xue‐tao Li
目的由于抗肿瘤药物的靶向性差和肿瘤的自适应性，卵巢癌的化疗效果仍然不佳。近年来，纳米靶向药物治疗肿瘤已成为一个潜在的研究热点。本研究构建了一种新型的短细胞穿透肽RPV修饰的紫杉醇加五味子乙素B脂质体，通过阻断VM通道、血管生成、增殖和迁移来治疗卵巢癌。采用CAM和模拟实验检测RPV修饰的脂质体处理前后对卵巢癌SK-OV-3细胞的影响。结果RPV修饰的紫杉醇联合五味子醇B脂质体能抑制卵巢癌SK-OV-3细胞的血管生成、VM通道形成、侵袭和增殖。体内外研究表明，肿瘤相关蛋白表达下调。RPV的修饰可以延长脂质体在体内的滞留时间，并在肿瘤部位蓄积，提高抗肿瘤疗效，具有重要意义RPV修饰的紫杉醇-五味子醇B脂质体具有良好的抗肿瘤作用，可能为卵巢癌的治疗提供新的途径。
AimsDue to poor targeting ability of anti-tumor drugs and self-adaptation of tumors, the chemotherapy of ovarian cancer is still poorly effective. In recent years, the treatment of tumor with nano-targeted agents has become a potential research focus. In this study, a new type of short cell-penetrating peptide RPV-modified paclitaxel plus schisandrin B liposomes were constructed to disrupt VM channels, angiogenesis, proliferation and migration for the treatment of ovarian cancer.Materials and methodsIn this study, clone assay, TUNEL, Transwell, wound-healing, CAM and mimics assay were used to detect the effects of RPV-modified liposomes on ovarian cancer SK-OV-3 cells before and after treatment. HE-staining, immunofluorescence and ELISA were used to further detect the expression of tumor-related proteins.Key findingsRPV-modified paclitaxel plus schisandrin B liposomes can inhibit angiogenesis, VM channel formation, invasion and proliferation of ovarian SK-OV-3 cells. In vitro and in vivo studies showed that tumor-related protein expression was down-regulated. Modification of RPV can prolong the retention time of liposome in vivo and accumulate in the tumor site, increasing the anti-tumor efficacy.SignificanceThe RPV-modified paclitaxel plus schisandrin B liposomes have good anti-tumor effect, thus may provide a new avenue for the treatment of ovarian cancer.